Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

WuXi adds plants to Changzhou complex

by Rick Mullin
August 8, 2022 | A version of this story appeared in Volume 100, Issue 27

A synthesizer and synthesis column at WuXi's new oligonucleotide plant.
Credit: WuXi
A synthesizer and synthesis column at WuXi's new oligonucleotide plant

WuXi STA, the pharmaceutical contract services division of WuXi AppTec, has expanded oligonucleotide and peptide manufacturing with a new large-scale facility at its Changzhou, China, complex. The 2,840 m2 oligonucleotide plant includes four large-scale production lines and more than 20 smaller units, increasing the capacity for a single synthesis run from 1.9 mol to 6.0 mol. The 2,068 m2 peptide plant features three production lines with reactors that accommodate up to 1,000 L, increasing WuXi’s total reactor volume for solid-phase peptide synthesis to 6,490 L. The company announced the opening of a plant for high-potency active pharmaceutical ingredients at Changzhou in June, and last month, the opening of a continuous manufacturing plant at the site.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.